

# Best of SABCS® 2025 Bulgaria

Highlights from the San Antonio Breast Cancer Symposium® 2025

13–14 February 2026

## SCIENTIFIC PROGRAM

### Friday, 13 February 2026

**11:00 – 18:00** *Registration*

**14:00 – 14:05** **Official opening**

*Assoc. Prof. Assia Konsoulova, MD, PhD*

**14:05 – 14:40**

**The Patient Voice:** Treatment de-escalation and personalization – mutual adaptation of physicians and patients

*Gergana Bogdanova, Stanimir Kacheshmarov, MD; Assoc. Prof. Assia Konsoulova, MD, PhD*

**14:45 – 15:30** **SABCS® 2025 Module 1**

**AI-assisted screening and risk prediction in breast cancer**

*Bozhidar Iliev, MD*

**GRADE-formatted panel discussion**

Moderator: *Lyubomir Balabanski, MD, DSc*

**15:35 – 16:20**

**Industry-supported symposium (MSD)**

**Multidisciplinary approach to the treatment of triple-negative breast cancer**

*Assoc. Prof. Assia Konsoulova, MD, PhD*

*Petya Balikova, MD*

*Valentin Ivanov, MD*

**16:20 – 16:45** *Coffee Break*

**16:45 – 17:30** **SABCS® 2025 Module 2**

**Quality of life and survivorship in breast cancer patients**

*Petya Balikova, MD*

**GRADE-formatted panel discussion**

Moderator: *Bozhidar Iliev, MD*

**17:35 – 18:20**

**Industry-supported symposium (Novartis)**

Moderator: *Assoc. Prof. Dimitar Kalev, MD, PhD*

What new did the 5-year data from the NATALEE study prove?

*Nadejda Miteva, MD*

Challenges in lobular carcinoma and long-term effectiveness of *Ribociclib*

*Radoslav Mangaldjiev, MD*

**18:25 – 18:50**

**Industry-supported symposium (Pfizer)**

Real-world PFS2 and tumor response by CDK4/6 in patients with HR+/HER2 metastatic breast cancer and other highlights from SABCS 2025

*Vasil Popov, MD*

**19:00** *Dinner*

**Saturday, 14 February 2026**

**08:00 – 17:30** *Registration*

**09:00 – 09:45 SABCS® 2025 Module 3**

**Biomarkers in breast cancer: certainty of evidence for predictive versus prognostic utility**

*Lyubomir Balabanski, MD, DSc*

**GRADE-formatted panel discussion**

Moderator: *Assoc. Prof. Assia Konsoulova, MD, PhD*

**09:50 – 10:20 SABCS® 2025 Module 4**

**Pathological tools for prediction of treatment response**

*Fyodor Odzhakov, MD, PhD*

**GRADE-formatted panel discussion**

Moderator: *Assoc. Prof. Svitlana Bachurska, MD, PhD*

**10:20 – 10:45** *Coffee Break*

**10:45 – 11:15 SABCS® 2025 Module 5**

**Magnetic resonance imaging (MRI) in breast cancer: indications and strategies. mPERCIST criteria in metastatic bone disease**

*Viktor Yordanov, MD; Assoc. Prof. Valeria Hadzhiyska, MD, PhD*

**GRADE-formatted panel discussion**

Moderator: *Assoc. Prof. Valeria Hadzhiyska, MD, PhD*

**11:20 – 11:45**

**Industry-Supported Symposium (Eli Lilly)**

**Verzenio – stable over time and proven to reduce the risk of relapse after 2 years of therapy in HR+/HER2- early breast cancer with lymph node involvement**

Treatment of HR+/HER2- early breast cancer with lymph node involvement – data from real practice

*Melek Musin*

Patients with HR+/HER2- metastatic breast cancer and high risk of progression – final data from the Monarch 2 and Monarch 3 studies

*Yavor Hinov, MD*

**11:50 – 12:15**

**Industry-Supported Symposium (Roche)**

**One for all or all for one**

What is the future of HER2+ mBC

*Petya Balikova, MD*

**12:20 – 12:45**

### **Симпозиум, подкрепен от индустрията (Swixx)**

*Sacituzumab govitecan*: modern interpretation of data in the treatment of mTNBC and HR+/HER2- breast cancer

Assoc. Prof. Assia Konsoulova, MD, PhD

**12:45 – 13:30 Lunch**

**13:30 – 14:15**

#### **SABCS® 2025 Module 6**

**Surgical minimalism in breast cancer: defining the limits**

*Slavyana Usheva, MD*

**GRADE-formatted panel discussion**

Moderator: *Valentin Ivanov, MD*

**14:20 – 14:50 SABCS® 2025 Module 7**

**De-escalation strategies in radiation therapy for breast cancer**

*Doroteya Ivanova, MD*

**GRADE-formatted panel discussion**

Moderator: *Assoc. Prof. Veselin Popov, MD, PhD*

**14:55 – 15:40**

### **Industry-Supported Symposium (AstraZeneca)**

**Therapies that are changing the treatment approach for metastatic HR+ breast cancer**

*Assoc. Prof. Assia Konsoulova, MD, PhD*

*Assoc. Prof. Dimitar Kaley, MD, PhD*

**15:45 – 16:30 SABCS® 2025 Module 8**

**Systemic therapy in Early Breast Cancer**

*Assoc. Prof. Assia Konsoulova, MD, PhD; Yavor Hinov, MD*

**GRADE-formatted panel discussion**

Moderator: *Assoc. Prof. Assia Konsoulova, MD, PhD*

**16:30 – 16:45 Coffee Break**

**16:45 – 17:30 SABCS® 2025 Module 9**

**Metastatic luminal HER2-negative breast cancer**

*Dimo Manov, MD*

**GRADE-formatted panel discussion**

Moderator: *Assoc. Prof. Assia Konsoulova, MD, PhD*

**17:35 – 18:20 SABCS® 2025 Module 10**

**Metastatic HER2-positive and triple-negative breast cancer**

*Teodora Karanikolova, MD*

**GRADE-formatted panel discussion**

Moderator: *Dimo Manov, MD*

**18:25 – 19:25**

**SABCS® 2025: practice-changing evidence from Monday onward**

**Expert position statement of the Bulgarian Joint Cancer Network (BJCN)**

*Assoc. Prof. Assia Konsoulova, MD, PhD*

**19:25 – 19:30 Official Closing**

*Assoc. Prof. Assia Konsoulova, MD, PhD*

**20:00 Dinner**